The current status of hormone treatment for prostate cancer patients in Korean real-world practice: a multi-institutional observational study

被引:5
作者
Kim, Jung Kwon [1 ]
Kim, Jung Jun [1 ]
Gang, Taek Won [2 ]
Kwon, Tae Kyun [3 ]
Kim, Hong Sup [4 ]
Park, Seung Chul [5 ]
Park, Jae-Shin [6 ]
Park, Jong-Yeon [7 ]
Yoon, Seok Joong [8 ]
Jeon, Youn-Soo [9 ]
Cho, Jin Seon [10 ]
Joo, Kwan Joong [11 ]
Hong, Sung-Hoo [12 ]
Byun, Seok-Soo [1 ]
机构
[1] Seoul Natl Univ, Dept Urol, Bundang Hosp, Seongnam 13620, South Korea
[2] Chonnam Natl Univ Hosp, Dept Urol, Gwangju 61469, South Korea
[3] Kyungpook Natl Univ, Sch Med, Med Ctr, Daegu 41404, South Korea
[4] Konkuk Univ, Dept Urol, Med Ctr, Seoul 05080, South Korea
[5] Wonkwang Univ Hosp, Dept Urol, Iksan 54538, South Korea
[6] Daegu Catholic Univ, Dept Urol, Med Ctr, Daegu 41911, South Korea
[7] Ulsan Univ, Gangneung Asan Hosp, Dept Urol, Kangnung 25440, South Korea
[8] Chungbuk Natl Univ Hosp, Dept Urol, Cheongju 28644, South Korea
[9] Soonchunhyang Univ Hosp, Dept Urol, Cheonan 31151, South Korea
[10] Hallym Univ, Dept Urol, Sacred Heart Hosp, Anyang 14068, South Korea
[11] Kangbuk Samsung Hosp, Dept Urol, Seoul 03181, South Korea
[12] Seoul St Mary Hosp, Dept Urol, Seoul 06591, South Korea
关键词
efficacy; hormonal treatment; Korean population; prostate cancer; safety; trend; ANDROGEN-DEPRIVATION THERAPY; QUALITY-OF-LIFE; CARDIOVASCULAR-DISEASE; 80; MG; TESTOSTERONE; MONOTHERAPY; SECONDARY; BLOCKADE; AGONIST; URINARY;
D O I
10.4103/aja.aja_95_18
中图分类号
R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
摘要
We aimed to evaluate the current nationwide trend, efficacy, safety, and quality of life (QoL) profiles of hormone treatment in real-world practice settings for prostate cancer (PCa) patients in Korea. A total of 292 men with any biopsy-proven PCa (TanyNanyMany) from 12 institutions in Korea were included in this multi-institutional, observational study of prospectively collected data. All luteinizing hormone-releasing hormone (LHRH) agonists were allowed to be investigational drugs. Efficacy was defined as (1) the rate of castration (serum testosterone <= 50 ng dl(-1)) at 4-week visit and (2) breakthrough (serum testosterone >50 ng dl(-1) after castration). Safety assessments included routine examinations for potential adverse events, laboratory tests, blood pressure, body weight, and bone mineral density (BMD, at baseline and at the last follow-up visit). QoL was assessed using the Expanded Prostate Cancer Index Composite-26 (EPIC-26). The most common initial therapeutic regimen was LHRH agonist with anti-androgen (78.0%), and the most commonly used LHRH agonist for combination and monotherapy was leuprolide (64.0% for combination and 58.0% for monotherapy). The castration and breakthrough rates were 78.4% and 6.6%, respectively. The laboratory results related to dyslipidemia worsened after 4 weeks of hormone treatment. In addition, the mean BMD T-score was significantly lower at the last follow-up (mean: -1.950) compared to baseline (mean: -0.195). The mean total EPIC-26 score decreased from 84.8 (standard deviation (s.d.]: 12.2) to 78.3 (s.d.: 8.1), with significant deterioration only in the urinary domain (mean: 23.5 at baseline and 21.9 at the 4-week visit). These findings demonstrate the nationwide trend of current practice settings in hormone treatment for PCa in Korea.
引用
收藏
页码:115 / +
页数:11
相关论文
共 31 条
[11]   Cost-effectiveness analysis of LHRH agonists in the treatment of metastatic prostate cancer in Italy [J].
Iannazzo, S. ;
Pradelli, L. ;
Carsi, M. ;
Perachino, M. .
VALUE IN HEALTH, 2011, 14 (01) :80-89
[12]   Survival of Korean Adult Cancer Patients by Stage at Diagnosis, 2006-2010: National Cancer Registry Study [J].
Jung, Kyu-Won ;
Won, Young-Joo ;
Kong, Hyun-Joo ;
Oh, Chang-Mo ;
Shin, Aesun ;
Lee, Jin-Soo .
CANCER RESEARCH AND TREATMENT, 2013, 45 (03) :162-171
[13]   Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer [J].
Keating, Nancy L. ;
O'Malley, A. James ;
Smith, Matthew R. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (27) :4448-4456
[14]   A re-assessment of the role of combined androgen blockade for advanced prostate cancer [J].
Klotz, L ;
Schellhammer, P ;
Carroll, K .
BJU INTERNATIONAL, 2004, 93 (09) :1177-1182
[15]   Nadir Testosterone Within First Year of Androgen-Deprivation Therapy (ADT) Predicts for Time to Castration-Resistant Progression: A Secondary Analysis of the PR-7 Trial of Intermittent Versus Continuous ADT [J].
Klotz, Laurence ;
O'Callaghan, Chris ;
Ding, Keyue ;
Toren, Paul ;
Dearnaley, David ;
Higano, Celestia S. ;
Horwitz, Eric ;
Malone, Shawn ;
Goldenberg, Larry ;
Gospodarowicz, Mary ;
Crook, Juanita M. .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (10) :1151-1156
[16]   Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk A Science Advisory From the American Heart Association, American Cancer Society, and American Urological Association Endorsed by the American Society for Radiation Oncology [J].
Levine, Glenn N. ;
D'Amico, Anthony V. ;
Berger, Peter ;
Clark, Peter E. ;
Eckel, Robert H. ;
Keating, Nancy L. ;
Milani, Richard V. ;
Sagalowsky, Arthur I. ;
Smith, Matthew R. ;
Zakai, Neil .
CIRCULATION, 2010, 121 (06) :833-840
[17]   Treatment costs for advanced prostate cancer using luteinizing hormone-releasing hormone agonists: a solid biodegradable leuprorelin implant versus other formulations [J].
Merseburger, Axel S. ;
Bjoerk, Thomas ;
Whitehouse, James ;
Meani, Davide .
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2015, 4 (05) :447-453
[18]   Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: The case for monitoring serum testosterone and a treatment decision algorithm [J].
Oefelein, MG ;
Cornum, R .
JOURNAL OF UROLOGY, 2000, 164 (03) :726-729
[19]   Contemporary Role of Androgen Deprivation Therapy for Prostate Cancer [J].
Pagliarulo, Vincenzo ;
Bracarda, Sergio ;
Eisenberger, Mario A. ;
Mottet, Nicolas ;
Schroeder, Fritz H. ;
Sternberg, Cora N. ;
Studer, Urs E. .
EUROPEAN UROLOGY, 2012, 61 (01) :11-25
[20]   Rising prostate cancer rates in South Korea [J].
Park, Sue Kyung ;
Sakoda, Lori C. ;
Kang, Daehee ;
Chokkalingam, Anand P. ;
Lee, Eunsik ;
Shin, Hai-Rim ;
Ahn, Yoon-Ok ;
Shin, Myung-Hee ;
Lee, Choong-Won ;
Lee, Duk-Hee ;
Blair, Aaron ;
Devesa, Susan S. ;
Hsing, Ann W. .
PROSTATE, 2006, 66 (12) :1285-1291